Current Clinical Trials
A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers. They are also called “participants.” Clinical Trials FAQs.
Find a Clinical Trial
| Therapeutic Area | Condition | Description | |
|---|---|---|---|
| Bleeding Disorders |
Hemophilia A | An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A. | Learn More |
| Hemophilia B | A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B | Learn More | |
| Hemophilia A & B | A Study to Investigate the Pharmacokinetics, Efficacy, and Safety of rVIIa-FP (CSL 689) in Subjects With Hemophilia (A or B) and Inhibitors | Learn More | |
| Congenital Fibrinogen Deficiency | An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency | Completed | |
| Von Willebrand Disease | Study of Voncento® in Subjects With Von Willebrand Disease | Completed | |
| Warfarin Reversal | An Observational Study of the Risk of Thromboembolic Events Among Adult Patients Treated With KCENTRA® Compared With Plasma for Urgent Reversal of Vitamin K Antagonist Therapy in the Setting of Acute Major Bleeding | Learn More | |
| Cardiovascular | Acute Coronary Syndrome | Study to investigate CSL112 in Subjects With Acute Coronary Syndrome | Learn More |
| Immunoglobulins | Chronic Inflammatory Demyelinating Polyneuropathy | Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Completed |
| Primary Immune Deficiency | Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (IgPro20, Hizentra) on Weekly and Biweekly Schedules | Completed | |
| Primary Immune Deficiency | Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) | Learn More | |
| Therapeutic Proteins | Other Inflammatory or immune system disorders | Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults | Learn More |
| Transplant | Antibody-mediated kidney transplant rejection | Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients | Learn More |
Get our latest news in your inbox
Thanks!
Thank you for subscribing
to the CSL newsletter